HBM HEALTHCARE INVESTMENTS AG

(HBMN)
  Report
Delayed Swiss Exchange  -  05/24 11:31:40 am EDT
256.00 CHF   +0.20%
05/18HBM Healthcare Investments AG Reports Earnings Results for the Full Year Ended March 31, 2022
CI
05/18Publication of Annual Report 2021/2022 and Invitation to the Ordinary Shareholders? Meeting
EQ
05/16Key Figures 15.05.2022
EQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

HBM Healthcare Investments delivers strong return despite weak biotech sector and increases net asset value per share (NAV) by 19 percent in calendar year 2021

01/03/2022 | 11:49am EDT

EQS-Ad-hoc: HBM Healthcare Investments AG / Key word(s): Quarter Results
HBM Healthcare Investments delivers strong return despite weak biotech sector and increases net asset value per share (NAV) by 19 percent in calendar year 2021

03-Jan-2022 / 17:46 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.


HBM Healthcare Investments closes the 2021 calendar year with another strong performance. The net asset value per share (NAV) rose by 19 percent to CHF 336.27 as at 31 December 2021, while the share price increased by 15.2 percent to close at CHF 339.00 at a small premium to NAV.

The healthcare sector showed a mixed picture in terms of performance. While the large-cap pharmaceutical companies (MSCI World Healthcare Index +23.9 percent, measured in Swiss francs) rose strongly in value, biotech companies (Nasdaq Biotechnology Index +3.0% and SPDR S&P Biotech ETF -18.1%) took a breather after their good run in recent years.

HBM Healthcare Investments, which is mainly invested in the segment of small and medium sized biotech companies, was able to more than compensate for the significant share price declines in this segment thanks to the strong share price performance of its largest listed investment, the Chinese Cathay Biotech (share price +118%), value contributions from the portfolio of private companies (financing rounds and IPOs), and partial profit realisations in the portfolio of listed companies.

Expected net profit of around CHF 275 million for the first 9 months of the financial year 2021/2022

Also for the first 9 months of the financial year 2021/2022 ending on 31 March, there was an increase in value of 12.8 percent in the NAV and of 5.7 percent in the share price (MSCI World Health Care Index +15.4%, NBI -2.7%, XBI -20.2%). Based on the reported NAV as at 31 December 2021, HBM Healthcare Investments expects a net profit of approximately CHF 275 million for this period (previous year net profit of CHF 644.6 million). In the case of an investment company, the net result reflects the changes in the value of the investments held.

The present figures are preliminary based on the current status of the financial closing process. The final result will be published with the December 2021 quarterly report on 21 January 2022.

Contact
For further information, please contact Dr Andreas Wicki on +41 41 710 75 77, or at andreas.wicki@hbmhealthcare.com.



End of ad hoc announcement
Language: English
Company: HBM Healthcare Investments AG
Bundesplatz 1
6300 Zug
Switzerland
Phone: +41438887171
Fax: +41438887172
E-mail: info@hbmhealthcare.com
Internet: https://www.hbmhealthcare.com
ISIN: CH0012627250
Valor: 1262725
Listed: SIX Swiss Exchange
EQS News ID: 1264387

 
End of Announcement EQS News Service

1264387  03-Jan-2022 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1264387&application_name=news&site_id=zonebourse_sftp

© EQS 2022
All news about HBM HEALTHCARE INVESTMENTS AG
05/18HBM Healthcare Investments AG Reports Earnings Results for the Full Year Ended March 31..
CI
05/18Publication of Annual Report 2021/2022 and Invitation to the Ordinary Shareholders? Mee..
EQ
05/16Key Figures 15.05.2022
EQ
05/10Pfizer to acquire HBM portfolio company Biohaven Pharmaceuticals in USD 11.6 billion de..
EQ
05/06HBM Healthcare Investments Sinks To FY22 Loss On Negative Result From Investment Activi..
MT
05/06HBM Healthcare Investments year-end results 2021/2022
EQ
05/02HBM Healthcare Investments Sees 3% Drop in April NAV
MT
05/02HBM HEALTHCARE INVESTMENTS : Key Figures 30.04.2022
PU
05/02Key Figures 30.04.2022
EQ
04/19HBM HEALTHCARE INVESTMENTS : Key Figures 15.04.2022
PU
More news
Analyst Recommendations on HBM HEALTHCARE INVESTMENTS AG
More recommendations
Financials
Sales 2023 412 M 429 M 429 M
Net income 2023 359 M 374 M 374 M
Net cash 2023 176 M 183 M 183 M
P/E ratio 2023 4,96x
Yield 2023 3,11%
Capitalization 1 781 M 1 855 M 1 855 M
EV / Sales 2023 3,90x
EV / Sales 2024 3,39x
Nbr of Employees 700
Free-Float 83,8%
Chart HBM HEALTHCARE INVESTMENTS AG
Duration : Period :
HBM Healthcare Investments AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends HBM HEALTHCARE INVESTMENTS AG
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 256,00 CHF
Average target price 370,00 CHF
Spread / Average Target 44,5%
EPS Revisions
Managers and Directors
Andreas Wicki Chief Executive Officer
Erwin Troxler Chief Financial Officer
Hans-Peter Hasler Chairman
Rudolf Lanz Director
Mario Germano Giuliani Director
Sector and Competitors